Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Spero Therapeutics, Inc. (SPRO)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
0.9400-0.1100 (-10.48%)
At close: 04:00PM EDT
0.9700 +0.03 (+3.19%)
After hours: 07:05PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Relative Strength Index (RSI)

Relative Strength Index (RSI)

Previous Close1.0500
Open1.0300
Bid0.9400 x 1400
Ask0.9800 x 1200
Day's Range0.9400 - 1.1400
52 Week Range0.8550 - 19.8700
Volume2,918,056
Avg. Volume753,998
Market Cap30.852M
Beta (5Y Monthly)1.92
PE Ratio (TTM)N/A
EPS (TTM)-3.2550
Earnings DateAug 03, 2022 - Aug 08, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.80
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for SPRO

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Spero Therapeutics, Inc.
    Analyst Report: Merck & Co., Inc.Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
    Rating
    Fair Value
    Economic Moat
    4 days agoMorningstar
View more
  • Skift

    History of Short-Term Rentals Filled With Arrogance and Missed Opportunities

    Looking back at the history of short-term rentals coming online starting in the mid-1990s, it’s easy to see how arrogant thinking and missed opportunities left their mark, and swayed the sector’s trajectory. That’s an easy takeaway from Skift’s recently published three-part Definitive Oral History of Short-Term Rentals because this theme of opportunities seized and lost […]

  • Zacks

    Spero Therapeutics, Inc. (SPRO) Reports Q1 Loss, Lags Revenue Estimates

    Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of -16.09% and 27.40%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Spero Therapeutics Announces First Quarter 2022 Operating Results and Provides Business Update

    New Strategic Direction Focuses on Advancing the Clinical Stage Pipeline and Identifying Tebipenem’s Optimal Path to Value Creation Initiation of a Phase 2 Trial of SPR720 in Nontuberculous Mycobacterial-Pulmonary Disease Expected in 2H 2022 SPR206’s Phase 1 Data Support Further Development in Complicated Urinary Tract Infection, Hospital-acquired and Ventilator-associated Bacterial Pneumonia, and Bloodstream Infections Conference Call and Live Webcast at 4:30 p.m. ET Today CAMBRIDGE, Mass., May

Advertisement
Advertisement